NCCN Guidelines® Insights - Prostate Cancer, Version 1.2016
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel’s most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Prostate Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
James L. Mohler, MD, Panel Chair, has disclosed that he has no relevant relationships.
Andrew J. Armstrong, MD, Panel Member, has disclosed that he receives grant/research support from Active Biotech AB; Bayer HealthCare; Dendreon Corporation; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Medivation, Inc.; and sanofi-aventis U.S. He receives consulting fees and honoraria from Active Biotech AB, Bayer HealthCare, and sanofi-aventis U.S.; is on the product/speakers bureau for Dendreon Corporation and sanofi-aventis U.S.; and is a scientific advisor for Bayer HealthCare.
Anthony Victor D’Amico, MD, PhD, Panel Member, has disclosed that he has no relevant relationships.
Brian J. Davis, MD, PhD, Panel Member, has disclosed that he and his spouse hold stock options in Pfizer Inc.; he receives honoraria from ASTRO and UpToDate.
Celestia S. Higano, MD, Panel Member, has disclosed that she receives grant/research support from Bayer HealthCare, Emergent BioSolutions Inc., AstraZeneca Pharmaceuticals LP, and sanofi-aventis U.S. She receives consulting/honoraria from BHR Pharma, LLC; Orion Corporation; Emergent BioSolutions Inc.; Bayer HealthCare; Churchill Pharmaceuticals LLC; Astellas US LLC; and Blue Earth Diagnostics Limited.
Eric Mark Horwitz, MD, Panel Member, has disclosed that he has no relevant relationships.
Michael Hurwitz, MD, PhD, Panel Member, has disclosed that he receives salary from Pfizer Inc.
Christopher J. Kane, MD, Panel Member, has disclosed that he received consulting fees from Janssen Pharmaceuticals, Inc.; Genomic Health, Inc.; and Myriad Genetics, Inc.; he receives research support from GenomeDx Biosciences Inc.; and is a scientific advisor for Tokai Pharmaceuticals, Inc.
Michael Kuettel, MD, MBA, PhD, Panel Member, has disclosed that he has no relevant relationships.
David F. Penson, MD, MPH, Panel Member, has disclosed that he receives grant/research support from Astellas US LLC and Medivation, Inc.; and receives consulting fees from Astellas US LLC.
Julio M. Pow-Sang, MD, Panel Member, has disclosed that he has no relevant relationships. Edward Schaeffer, MD, PhD, Panel Member, has disclosed that he receives consulting fees from GenomeDx Biosciences Inc., and is a scientific advisor for Myriad Genetics, Inc.
Dorothy A. Shead, MS, Director, Patient & Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-16-001-H01-P
All clinicians completing this activity will be issued a certificate of participation.
Release date: January 1, 2016
Expiration date: January 1, 2017
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation